Our genetically-engineered, universal iPSCs-derived immune effector cell products (NK, T, Dendritic cells, and macrophage) are designed to specifically target hematologic and solid tumor cancers. Our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care. Please note Century Therapeutics does not solicit prospective Colleagues directly via Telegram (or other social media sites), or require potential candidates to make purchases of goods or services.